Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.

Velocity Clinical Research partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials ...

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.